Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 14/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 3/20 | 0.48 |
| ▸ | ACHE | P22303 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19834813 | 0.91 | NAMPT (0.70) | NAMPTCYP3A4CYP2C9DRD2DRD3 | |
| SCHEMBL19834857 | 0.86 | NAMPT (0.73) | NAMPTCYP3A4CYP2C9DRD2DRD3 | |
| SCHEMBL19834844 | 0.85 | NAMPT (0.69) | NAMPTCYP3A4CYP2C9DRD2DRD3 | |
| SCHEMBL19834842 | 0.84 | NAMPT (0.69) | NAMPTCYP3A4CYP2C9DRD2DRD3 | |
| SCHEMBL20095396 | 0.82 | NAMPT (0.79) | NAMPTCYP3A4CYP2C9 | |
| SCHEMBL82563 | 0.82 | NAMPT (0.78) | NAMPTCYP3A4CYP2C9DRD2DRD3 | |
| SCHEMBL82564 | 0.82 | NAMPT (0.78) | NAMPTCYP3A4CYP2C9DRD2DRD3 | |
| SCHEMBL22654247 | 0.81 | NAMPT (0.78) | NAMPTCYP3A4CYP2C9 | |
| SCHEMBL20095467 | 0.81 | NAMPT (0.78) | NAMPTCYP3A4CYP2C9 | |
| Daporinad SCHEMBL156944 | 0.81 | NAMPT (1.00) | NAMPTCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190185452-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV (CH) | 2019-06-20 | — | — | US | claimed |
| US-10894785-B2 | Piperidine derivatives for use in the treatment of pancreatic cancer | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV | 2021-01-19 | — | — | US | disclosed |
| US-10894785-B2 | Piperidine derivatives for use in the treatment of pancreatic cancer | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV | 2021-01-19 | — | — | US | disclosed |
| US-20190185452-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV (CH) | 2019-06-20 | — | — | US | disclosed |
| US-20190185452-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV (CH) | 2019-06-20 | — | — | US | disclosed |
| EP-3279192-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | Centre Hospitalier Universitaire Vaudois (CHUV) (CH) | 2018-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894785-B2 | Piperidine derivatives for use in the treatment of pancreatic cancer | RNASE1, PKD1, GPR6 | NAMPT 1437/4885CYP3A4 2988/4885CYP2C9 4330/4885 |
| US-20190185452-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | RNASE1, PKD1, GPR6 | NAMPT 1265/4885CYP3A4 2393/4885CYP2C9 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.